Feneck Robert
Department of Anaesthesia, Guys and St Thomas' Hospitals, London, England.
Drugs. 2007;67(14):2023-44. doi: 10.2165/00003495-200767140-00005.
The management of hypertension continues to pose important challenges. Recent developments have established the importance of more rigorous blood pressure control in the community. In the perioperative setting, hypertension has long been recognised as undesirable, although the adverse impact of high blood pressure on the acute risks of elective surgery may have been previously overstated.A number of agents and techniques are available to control blood pressure perioperatively. These include principally general and regional anaesthetics, alpha(2)-adrenoceptor agonists, peripheral alpha(1)- and beta-adrenoceptor antagonists, dihydropyridine calcium channel antagonists, dopamine D(1A)-receptor agonists (fenoldopam), and nitric oxide donors. Recent years have seen important developments in the receptor selectivity of new compounds and in pharmacokinetics, particularly esterase metabolism. The future study of genomics may enable us to identify patients at risk for hypertension-related adverse events and target therapies most effectively to these high-risk groups.
高血压的管理仍然面临着重大挑战。最近的进展已证实了在社区中更严格控制血压的重要性。在围手术期,高血压长期以来一直被认为是不良情况,尽管之前可能高估了高血压对择期手术急性风险的不利影响。围手术期有多种药物和技术可用于控制血压。这些主要包括全身麻醉和区域麻醉、α₂肾上腺素能受体激动剂、外周α₁和β肾上腺素能受体拮抗剂、二氢吡啶类钙通道拮抗剂、多巴胺D₁A受体激动剂(非诺多泮)以及一氧化氮供体。近年来,新化合物的受体选择性和药代动力学,尤其是酯酶代谢方面取得了重要进展。基因组学的未来研究可能使我们能够识别有高血压相关不良事件风险的患者,并最有效地针对这些高危人群进行靶向治疗。